Skip to content
Screener

Aclaris Therapeutics ACRS Single Reportable — General And Administrative Expense

Similar metrics at other companies

Alumis Inc. logo
ALMSSingle Reportable — General And Administrative Expense
$18.61M-16.5%
Capricor Therapeutics logo
CAPRSingle Reportable — General And Administrative Expense
$9.4M+54.9%
ALO
ALOVSingle Reportable — General And Administrative Expense
-$658.46K
Research Solutions logo
RSSSSingle Reportable — General And Administrative Expense
$1.63M-11.9%
Dogwood Therapeutics logo
DWTXSingle Reportable — General And Administrative Expense
$2.41M+20.8%
SilverBox logo
SBXDSingle Reportable — General And Administrative Expense
$495.37K+168%

Other financials

Income statement

See full
Revenue$1.6M-8.3%
Gross profit$1.4M+11.8%
Operating income-$24.2M-31.7%
Net income-$21.5M-39.4%
EPS (diluted)-$0.15-15.4%

Balance sheet

See full
Cash & equivalents$19.2M-24.5%
Total debt$1.9M-21.8%
Total equity$124.6M-5.4%
Total assets$179.7M-5.0%

Cash flow

See full
Operating cash flow-$19.8M-98.6%
CapEx$58.0K+176%
Free cash flow-$19.9M-98.8%

Valuation

See full
Market cap$868.56M+389%
Enterprise value$851.24M+451%
P/S105.7×+95.1×

Profitability

See full
Gross margin79.5%-6.3pp
Operating margin-1,050.2%+266pp
Net margin-921.5%+161pp
FCF margin-756.5%

Returns & leverage

See full
Return on equity-59.1%-17.4pp
Debt / equity0.0×
Current ratio3.5×-0.4×

Where this comes from

Reported directly by Aclaris Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: Aclaris Therapeutics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 4:31 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001104659-26-092065
(In thousands)Three Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Personnel3,0362,9846,3175,911
Other research and development(2)1,3981,4623,2972,962
Total research and development18,06611,44933,72323,033
General and administrative(3)6,0485,38612,79111,525
Licensing1,2351,3352,6282,345
Revaluation of contingent consideration3001,5003001,800
Segment operating loss$(24,238)$(18,408)$(46,430)$(36,492)
Other income2,7332,9795,1015,978

Item 1. Financial Statements

FAQ

What is Aclaris Therapeutics's single reportable — general and administrative expense?
Aclaris Therapeutics (ACRS) reported single reportable — general and administrative expense of $6.05M in Q2 2026.
How has Aclaris Therapeutics's single reportable — general and administrative expense changed year-over-year?
Aclaris Therapeutics's single reportable — general and administrative expense increased by 12.3% year-over-year, from $5.39M to $6.05M.
What does single reportable — general and administrative expense mean?
Represents the overhead costs required to support the segment's operations, including executive management, legal, finance, and other administrative functions. This metric is used to evaluate the efficiency of the segment's management and its ability to control non-core operational spending. It serves as a measure of the segment's administrative burden.

Ask your AI about Aclaris Therapeutics's single reportable — general and administrative expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude